Allurion Technologies, INC 10-Q quarterly reports

Allurion Technologies reports a significant revenue decline and net loss, triggering a 'going concern' warning while pursuing strategic restructuring and new financing.

Allurion Technologies, Inc. filed an amended quarterly report for Q3 2024, restating financials due to accounting errors and announcing a significant workforce reduction.

Allurion Technologies, Inc. has restated its Q2 2024 financials due to material weaknesses in internal controls, while facing a sales suspension in France and a NYSE delisting notice.

Allurion Technologies, Inc. filed an amended quarterly report to restate its Q1 2024 financial statements, revealing material weaknesses in internal controls and a significant revenue decline.

Allurion Technologies reports a significant revenue decline and increased net loss, leading to a major restructuring and raising substantial doubt about its ability to continue as a going concern.

Allurion Technologies, Inc. restated prior financial statements, revealing significant losses and material weaknesses in internal controls, while raising capital and addressing regulatory hurdles.

Allurion Technologies' Q1 2025 revenue decreased by 41% year-over-year to $5.6 million, reflecting strategic changes and market factors.

Allurion Technologies experienced a significant revenue decrease in Q3 2024, alongside a restructuring plan aimed at reducing operating costs.

Allurion Technologies reports a net income of $3.4 million for the six months ended June 30, 2024, a significant turnaround from a net loss of $39.8 million in the same period last year, while facing revenue declines and regulatory hurdles.

Allurion Technologies experienced a decrease in revenue during the first quarter of 2024, alongside a net income driven by changes in fair value of liabilities.